Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2020.2149
Abstract: Importance Since 2011, many patients with metastatic melanoma have been treated with ipilimumab therapy and have developed severe immune-related adverse events (AEs). Because several immune therapies are now available to treat metastatic melanoma, a better… read more here.
Keywords: therapy; related aes; immune related; metastatic melanoma ... See more keywords
Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients
Sign Up to like & getrecommendations! Published in 2017 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000313
Abstract: In patients with ipilimumab (IPI)-refractory melanoma, the anti-programmed cell death proteins 1 (PD1s) nivolumab (NIV) and pembrolizumab (PEM) are considered to be a new standard of treatment. Few data are available on anti-PD1 safety in… read more here.
Keywords: anti pd1; ipi; study; ipi related ... See more keywords
Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacy and therapeutics"
DOI: 10.1111/jcpt.13648
Abstract: WHAT IS KNOWN AND OBJECTIVES As for adverse events (AEs) caused by everolimus, findings from clinical trials and post-marketing surveillance have reported interstitial lung disease, hyperglycaemia, cardiovascular disease, etc. However, these reports are limited to… read more here.
Keywords: event; comprehensive analysis; adverse events; database ... See more keywords
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting
Sign Up to like & getrecommendations! Published in 2023 at "Antiviral Therapy"
DOI: 10.1177/13596535231163703
Abstract: Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in… read more here.
Keywords: related discontinuations; discontinuations adverse; treatment related; treatment ... See more keywords
Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1045561
Abstract: Background: The role of antihypertensive drugs in inducing hyperuricaemia and gout has been a long-term concern in clinical practice. However, clinical studies regarding this issue are limited in number and have yielded inconsistent results. We… read more here.
Keywords: antihypertensive drugs; gout related; related aes; hyperuricaemia gout ... See more keywords
Medical disputes related to advanced endoscopic procedures with endoscopic retrograde cholangiopancreatography or endoscopic ultrasonography for the management of pancreas and biliary tract diseases.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical endoscopy"
DOI: 10.5946/ce.2022.208
Abstract: Background/Aims This study aimed to evaluate the characteristics of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasonography (EUS)-related adverse events (AEs) that eventually lead to medical disputes or claims on medical professional liability. Methods Medical disputes… read more here.
Keywords: retrograde cholangiopancreatography; endoscopic; endoscopic ultrasonography; medical disputes ... See more keywords